The Medical Letter on Drugs and Therapeutics
An Oral Cholera Vaccine for Travelers (Vaxchora)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Vaxchora (PaxVax), a single-dose, oral, live-attenuated cholera vaccine, to protect against disease caused by Vibrio cholerae serogroup O1 in adults 18-64 years old traveling to cholera-affected areas. Vaxchora is the only cholera vaccine available in the US. A whole-cell killed injectable vaccine was previously approved, but is no longer available in the US.

CHOLERA INFECTION — Cholera is endemic in over 50 countries, primarily in Africa and South and Southeast Asia. In recent years, there have been outbreaks of cholera in some Caribbean nations, such as Haiti.1 V. cholerae is spread mainly by fecal contamination of water and food in countries without proper sanitation or clean drinking water. Ingestion of the toxigenic V. cholerae serogroups O1 or (less commonly) O139 causes diarrhea that can be severe and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: An Oral Cholera Vaccine for Travelers (Vaxchora)
Article code: 1502d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian